Clinical Trials
40 trialsNCT04929223 2026-05-26
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT07284849 2026-05-26
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT06598007 2026-05-19
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
Phase 1/2 Recruiting
NCT00959647 2026-05-08
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT06663319 2026-05-08
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07221357 2026-05-06
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06179160 2026-05-04
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
Phase 1 Recruiting
NCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT06917079 2026-03-23
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT06936527 2025-09-03
XS-03-II201
NovaOnco Therapeutics Co., Ltd.
Phase 1/2 Enrolling by invitation
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03597581 2025-04-03
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Inspirna, Inc.
Phase 1 Completed
NCT06225843 2025-02-19
EGIA-003
Alethia Biotherapeutics
Phase 2 Recruiting
NCT03526835 2025-01-29
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
Phase 1/2 Recruiting
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT05039944 2024-07-18
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT03043950 2024-04-24
VALIDATE
iOMEDICO AG
Completed
NCT00851136 2022-12-13
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
Phase 1 Completed
NCT00364013 2022-11-07
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Phase 3 Completed
NCT04145193 2020-09-21
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Phase 2 Withdrawn
NCT03035253 2020-08-11
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
Mereo BioPharma
Phase 1 Terminated
NCT00724503 2019-03-26
SIRFLOX
Sirtex Medical
Phase NA Completed
NCT00551213 2018-08-24
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03362684 2017-12-05
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
IntegraGen SA
Phase 3 Completed
NCT01418222 2017-05-30
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT00399035 2016-12-28
HORIZON II
AstraZeneca
Phase 3 Completed
NCT00873756 2016-11-02
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT02202928 2015-12-28
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT00440310 2015-08-25
Phase 3 Trial of Litxâ„¢ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Light Sciences Oncology
Phase 3 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00890305 2015-07-08
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Medivation, Inc.
Phase 2 Completed
NCT00778830 2015-05-14
APEC
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00349336 2012-09-18
A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT00866944 2011-11-11
MT201-204
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT00478946 2009-01-21
A Study of Picoplatin in Colorectal Cancer
Poniard Pharmaceuticals
Phase 1/2 Unknown